𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5

✍ Scribed by Myrthe P. P. van Herk-Sukel; Lonneke V. van de Poll-Franse; Adri C. Voogd; Grard A. P. Nieuwenhuijzen; Jan Willem W. Coebergh; Ron M. C. Herings

Book ID
106378575
Publisher
Springer US
Year
2010
Tongue
English
Weight
266 KB
Volume
122
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Influence of treatment with tamoxifen an
Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients
✍ Svein I. Helle; Jeff M. P. Holly; Michael Tally; Kerstin Hall; Jos Van Der Stapp πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 French βš– 540 KB

Plasma levels of IGF-I, IGFBP-I and IGFBP-3 were measured before and during treatment with tamoxifen up to 19+ months in 34 post-menopausal patients with advanced breast cancer. In 28 patients, pro-IGF-IIE (IGF-IIE) levels were determined and IGFBP-3 was evaluated by immunoblot in 27 patients. Tamox

Prognostic role of pregnancy occurring b
Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged <35 years : A GET(N)A Working Group analysis
✍ RΓ©my Largillier; Alexia Savignoni; Joseph Gligorov; Philippe Chollet; Marie-NoΓ«l πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 302 KB

## Abstract ## BACKGROUND: Usual practices recommend waiting at least 2 years between diagnosis of early breast cancer (EBC) and pregnancy. Few data highlighted a harmful effect of an early pregnancy for low‐risk patients. The authors analyzed retrospectively data from women younger than 35 years